Low Immunogenic Endothelial Cells Maintain Morphological and Functional Properties Required for Vascular Tissue Engineering

• Published in: Tissue engineering. Part A 2018-03, Vol.24 (5-6), p.432-447
• Main Authors: Lau, Skadi, Eicke, Dorothee, Carvalho Oliveira, Marco, Wiegmann, Bettina, Schrimpf, Claudia, Haverich, Axel, Blasczyk, Rainer, Wilhelmi, Mathias, Figueiredo, Constança, Böer, Ulrike
• Format: Article
• Language: English
• Subjects: Adipose tissue; Adult; Angiogenesis; Autografts; Biology; Biomedical engineering; Blood coagulation; Blood Vessel Prosthesis; Blood vessels; Bone marrow; Cadherins; Cord blood; Endothelial cells; Endothelial Cells - cytology; Endothelial Cells - immunology; Fetal Blood - cytology; Fetal Blood - immunology; Fibrin; Gels; Gene Silencing; Geriatrics; Hemodialysis; Histocompatibility antigen HLA; HLA Antigens - genetics; HLA Antigens - immunology; Humans; Immunogenicity; Male; Medical schools; Medicine; Mesenchyme; Morphology; Nitric oxide; Nitric-oxide synthase; Original Articles; Peripheral blood; R&D; Research & development; RNA-mediated interference; Shunts; Smooth muscle; Stem cells; Surface markers; Surgery; Tissue Engineering; Transplantation; Transplants & implants; Umbilical cord; Vascular surgery
• ISSN: 1937-3341; 1937-335X
• DOI: 10.1089/ten.tea.2016.0541

The limited availability of native vessels suitable for the application as hemodialysis shunts or bypass material demands new strategies in cardiovascular surgery. Tissue-engineered vascular grafts containing autologous cells are considered ideal vessel replacements due to the low risk of rejection. However, endothelial cells (EC), which are central components of natural blood vessels, are difficult to obtain from elderly patients of poor health. Umbilical cord blood represents a promising alternative source for EC, but their allogeneic origin corresponds with the risk of rejection after allotransplantation. To reduce this risk, the human leukocyte antigen class I (HLA I) complex was stably silenced by lentiviral vector-mediated RNA interference (RNAi) in EC from peripheral blood and umbilical cord blood and vein. EC from all three sources were transduced by 93.1% ± 4.8% and effectively, HLA I-silenced by up to 67% compared to nontransduced (NT) cells or transduced with a nonspecific short hairpin RNA, respectively. Silenced EC remained capable to express characteristic endothelial surface markers such as CD31 and vascular endothelial cadherin important for constructing a tight barrier, as well as von Willebrand factor and endothelial nitric oxide synthase important for blood coagulation and vessel tone regulation. Moreover, HLA I-silenced EC were still able to align under unidirectional flow, to take up acetylated low-density lipoprotein, and to form capillary-like tube structures in three-dimensional fibrin gels similar to NT cells. In particular, addition of adipose tissue-derived mesenchymal stem cells significantly improved tube formation capability of HLA I-silenced EC toward long and widely branched vascular networks necessary for prevascularizing vascular grafts. Thus, silencing HLA I by RNAi represents a promising technique to reduce the immunogenic potential of EC from three different sources without interfering with EC-specific morphological and functional properties required for vascular tissue engineering. This extends the spectrum of available cell sources from autologous to allogeneic sources, thereby accelerating the generation of tissue-engineered vascular grafts in acute clinical cases.